Challenges of antiangiogenic therapy of tumors

Roberta Sarmiento, Raffaele Longo, Giampietro Gasparini

Research output: Chapter in Book/Report/Conference proceedingChapter


After the approval of the first antiangiogenic agent, bevacizumab, in February 2004, a humanized monoclonal antibody anti-vascular endothelial growth factor (VEGF), this category of new anticancer drugs expanded rapidly. At the end of 2006, the U.S. Food and Drug Administration (FDA) approved bevacizumab for therapy of advanced colorectal and non-small cell lung cancers (except squamous cell histotype), sunitinib for advancedrefractory renal cancer and for imatinib-resistant gastro-intestinal stromal tumors (GISTs), and sorafenib for recurrent advanced kidney cancer. Twelve antiangiogenic drugs entered Phase III trials and at least another 15-20 are under evaluation in Phase I-II studies. Such a rapid clinical development of inhibitors of angiogenesis with different pharmacodynamic and pharmacokinetic characteristics opens a number of challenges, including: the identification of targets of choice; the optimal therapeutic strategy; the rational selection of the patients; proper study-design of clinical trials as well as the monitoring of drug efficacy; management of toxicity; and, finally, the determination of the disease stage to obtain the best benefit. All the above relevant issues are presented and discussed in this chapter.

Original languageEnglish
Title of host publicationAngiogenesis: An Integrative Approach From Science to Medicine
PublisherSpringer US
Number of pages15
ISBN (Print)9780387715179
Publication statusPublished - 2008


  • adverse events
  • clinical study endpoints
  • clinical trial design
  • endothelial cells
  • horizontal inhibition
  • vertical inhibiton

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Challenges of antiangiogenic therapy of tumors'. Together they form a unique fingerprint.

Cite this